Free Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 966 - 974
Section La révolution des anticorps modulateurs de la réponse immunitaire en oncologie
Published online 06 January 2020
  1. Vanhove B, Poirier N, Fakhouri F, et al. Antagonist anti-CD28 therapeutics for the treatment of autoimmune disorders. Antibodies 2017 ; 6: 19. [CrossRef] [Google Scholar]
  2. Oshima S, Karrer EE, Kawato Y, et al. The effect of ASP2409, a novel CD86-selective variant of CTLA4-Ig, on renal allograft rejection in nonhuman primates. Transplantation 2016 ; 100: 2611–2620. [CrossRef] [PubMed] [Google Scholar]
  3. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab’ antibody. Am J Transplant 2012 ; 12: 2630–2640. [Google Scholar]
  4. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363: 711–723. [Google Scholar]
  5. Arce Vargas F, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 2018; 33: 649–63 e4. [CrossRef] [PubMed] [Google Scholar]
  6. Tyrsin D, Chuvpilo S, Matskevich A, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016 ; 34: 45–48. [PubMed] [Google Scholar]
  7. Imai K, Matsuyama S, Miyake S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000 ; 356: 1795–1799. [CrossRef] [PubMed] [Google Scholar]
  8. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002 ; 99: 3661–3667. [Google Scholar]
  9. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015 ; 21: 938–945. [CrossRef] [PubMed] [Google Scholar]
  10. Harly C, Guillaume Y, Nedellec S, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood 2012 ; 120: 2269–2279. [Google Scholar]
  11. Melandri D, Zlatareva I, Chaleil RAG, et al. The gammadeltaTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nat Immunol 2018 ; 19: 1352–1365. [CrossRef] [PubMed] [Google Scholar]
  12. de Bruin RCG, Veluchamy JP, Lougheed SM, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vgamma9Vdelta2-T cells. Oncoimmunology 2017 ; 7: e1375641. [CrossRef] [PubMed] [Google Scholar]
  13. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006 ; 27: 211–217. [Google Scholar]
  14. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013 ; 13: 842–857. [Google Scholar]
  15. Bastid J, Cottalorda-Regairaz A, Alberici G, et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013 ; 32: 1743–1751. [Google Scholar]
  16. Antonioli L, Novitskiy SV, Sachsenmeier KF, et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov Today 2017 ; 22: 1686–1696. [CrossRef] [PubMed] [Google Scholar]
  17. Beavis PA, Milenkovski N, Stagg J, et al. A2A blockade enhances anti-metastatic immune responses. Oncoimmunology 2013 ; 2: e26705. [CrossRef] [PubMed] [Google Scholar]
  18. Iannone R, Miele L, Maiolino P, et al. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 2014 ; 4: 172–181. [Google Scholar]
  19. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009 ; 9: 259–270. [Google Scholar]
  20. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013 ; 19: 1264–1272. [CrossRef] [PubMed] [Google Scholar]
  21. Patwardhan PP, Surriga O, Beckman MJ, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res 2014 ; 20: 3146–3158. [CrossRef] [PubMed] [Google Scholar]
  22. Cannarile MA, Weisser M, Jacob W, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 2017 ; 5: 53. [Google Scholar]
  23. Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015 ; 16: 949–956. [CrossRef] [PubMed] [Google Scholar]
  24. Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 2015 ; 373: 428–437. [Google Scholar]
  25. Neubert NJ, Schmittnaegel M, Bordry N, et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med 2018; 10. [Google Scholar]
  26. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012 ; 109: 6662–6667. [CrossRef] [Google Scholar]
  27. Yanagita T, Murata Y, Tanaka D, et al. Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy. JCI Insight 2017 ; 2: e89140. [CrossRef] [PubMed] [Google Scholar]
  28. Burris HA, Infante JR, Ansell SM, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol 2017 ; 35: 2028–2036. [CrossRef] [PubMed] [Google Scholar]
  29. Poirier N, Chevalier M, Mary C, et al. Selective CD28 antagonist blunts memory immune responses and promotes long-term control of skin inflammation in nonhuman primates. J Immunol 2016 ; 196: 274–283. [CrossRef] [PubMed] [Google Scholar]
  30. Perrot I, Giraudon Paoli M, Augier S, et al. Preclinical development of humanized CD39 and CD73 blockingantibodies targeting the ATP/adenosine immune checkpoint pathway forcancer immunotherapy. Proceedings of the 2018 AACR annual meeting. Cancer Res 2018 (abstract #2718). [Google Scholar]
  31. Anil Kumar MS, Papp K, Tainaka R, et al. Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis. Biopharm Drug Dispos 2018 ; 39: 245–255. [CrossRef] [PubMed] [Google Scholar]
  32. Folkes AS, Feng M, Zain JM, et al. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. Curr Opin Oncol 2018 ; 30: 332–337. [CrossRef] [PubMed] [Google Scholar]
  33. Riether C, Schurch CM, Flury C, et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci Transl Med 2015; 7: 298ra119. [PubMed] [Google Scholar]
  34. Siu L, Burris H, Le DT, et al. Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. Proceedings of the 2018 AACR annual meeting. Cancer Res 2018 (abstract CT180). [Google Scholar]
  35. Vincenti F.. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016 ; 374: 2600–2601. [Google Scholar]
  36. Haegel H, Thioudellet C, Hallet R, et al. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells. MAbs 2013 ; 5: 736–747. [CrossRef] [PubMed] [Google Scholar]
  37. Pan PY, Zang Y, Weber K, et al. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 2002 ; 6: 528–536. [CrossRef] [PubMed] [Google Scholar]
  38. Chin SM, Kimberlin CR, Roe-Zurz Z, et al. Structure of the 4–1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat Commun 2018 ; 9: 4679. [PubMed] [Google Scholar]
  39. Tocoian A, Buchan P, Kirby H, et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus 2015 ; 24: 1045–1056. [PubMed] [Google Scholar]
  40. Durand J, Gauttier V, Morello A, et al. SIRPa inhibition monotherapy leads to dramatic change in solid tumor microenvironment and prevents metastasis development. Proceedings of the 2018 AACR annual meeting. Cancer Res 2018 (abstract 1753). [Google Scholar]
  41. Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011 ; 344: 269–278. [PubMed] [Google Scholar]
  42. Gauvreau GM, Boulet LP, Cockcroft DW, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 2014 ; 44: 29–37. [CrossRef] [PubMed] [Google Scholar]
  43. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018 ; 379: 2342–2350. [Google Scholar]
  44. O’Dwyer R, Kovaleva M, Zhang J, et al. Anti-ICOSL new antigen receptor domains inhibit T cell proliferation and reduce the development of inflammation in the collagen-induced mouse model of rheumatoid arthritis. J Immunol Res 2018 ; 2018: 4089459. [PubMed] [Google Scholar]
  45. Benzon B, Zhao SG, Haffner MC, et al. Correlation of B7–H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 2017 ; 20: 28–35. [CrossRef] [PubMed] [Google Scholar]
  46. Ribas A.. Tumor immunotherapy directed at PD-1. N Engl J Med 2012 ; 366: 2517–2519. [Google Scholar]
  47. Amatore F, Gorvel L, Olive D. Inducible co-stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin Ther Targets 2018 ; 22: 343–351. [CrossRef] [PubMed] [Google Scholar]
  48. Vey N, Karlin L, Sadot-Lebouvier S, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget 2018 ; 9: 17675–17688. [PubMed] [Google Scholar]
  49. Wang B, Zhang W, Jankovic V, et al. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype. Sci Immunol 2018; 3. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.